Welcome to the e-CCO Library Archive!

Filter:
DOP014.

The role of optineurin in macrophage cytokine secretion and Crohn's disease

Authors:

T.S. Chew1, A.M. Smith1, G.W. Sewell1, N.R. O'Shea1, S.L. Bloom2, A.W. Segal1, 1University College London, Centre for Molecular Medicine, London, United Kingdom, 2University College London Hospital, Department of Gastroenterology, London, United Kingdom

DOP014

Dietary patterns and risk of Inflammatory Bowel Disease in Europe: Results from the EPIC study

Authors:

A. Racine*1, F. Carbonnel1, S. Chan2, A. Hart2, B. Bueno de Mesquita3, B. Oldenburg4, F. VanSchaik4, A. Tjonneland5, A. Olsen5, C. Dahm6, T. Key7, R. Luben8, K.-T. Kaw9, E. Riboli10, O. Grip11, S. Lindgren11, G. HAllmans12, P. Karling13, F. Clavel-Chapelon14, M. Bergman15, H. Boeing15, B. Buijsse15, R. Kaaks16, V. Katzke17, D. Palli18, G. Masala18, P. Jantchou19, M.C. Boutron Ruault14

1University Hospital of Bicêtre, Assistance Publique Hôpitaux de Paris, Université Paris-Sud,, Department of Gastroenterology, Le Kremlin Bicetre, France, 2Norfolk and Norwich University Hospital NHS Trust, Departement of Medicine, Norwich, United Kingdom, 3National Institute for Public Health and the Environment (RIVM, Department. for Determinants of Chronic Diseases (DCD), , Bilthoven, Netherlands, 4University Medical Centre, Department . of Gastroenterology and Hepatology, Utrecht, Netherlands, 5Danish Cancer Society, Institute of Cancer Epidemiology, Copenhagen, Denmark, 6Aarhus University, Section for Epidemiology, Department of Public Health, Aarhus, Denmark, 7University of Oxford, , Cancer Epidemiology Unit, Nuffield Department of Clinical Medicine, Oxford, United Kingdom, 8University of Cambridge, , Strangeways Research Laboratory, Institute of Public Health, Cambridge, United Kingdom, 9University of Cambridge, Strangeways Research Laboratory, Institute of Public Health, Cambridge, United Kingdom, 10Imperial College London,, Division of Epidemiology, London, United Kingdom, 11University Hospital Malmö, , Department of Gastroenterology and Hepatology, Malmö, Sweden, 12Umea University, , Department of Public Health and Clinical Medicine, Nutritional Research, , Umea, Sweden, 13Umea University, Department of Public Health and Clinical Medicine, GI unit, Umea, Sweden, 14INSERM, Centre for Research in Epidemiology and Population Health, U1018, Team 9, Institut Gustave Roussy, Université Paris Sud, Villejuif, France, 15German Institute of Human Nutrition, , Department of Epidemiology, Potsdam, Germany, 16DKFZ-German Cancer Research Centre Heidelberg, , Division of Clinical Epidemiology, Heidelberg, Germany, 17DKFZ-German Cancer Research Centre Heidelberg, , Division of Clinicl Epidemiology, Heidelberg, Germany, 18Cancer Research and Prevention Institute – ISPO, Molecular and Nutritional Epidemiology Unit, Firenze, Italy, 19Sainte Justine University Hospital, Departement de Gastroenterologie hepatologie Nutrition Pediatrique, Montreal, Canada

DOP015.

Gut microbiota can induce autophagy in intestinal epithelial cells, a concern for Crohn's disease

Authors:

M.-L. Tran-Minh1, E. Quévrain1, L. Brot1, G. Thomas1, J.-P. Grill1, G. Trugnan1, P. Seksik1,2, 1INSERM, Université Paris 6, ERL U1057/UMR 7203, Paris, France, 2Hopital Saint Antoine, Gastro Enterologie, Paris, France

DOP015

Inflammatory bowel diseases in Israel: High prevalence suggested by health maintenance organizations administrative databases

Authors:

Y. Shachar1, M. Avitzour2, Y. Chowers3, R. Balicer4, N. Lederman5, E. Matz6, J. Rosenblum7, R. Eliakim8, S. Ben-Horin8, S. Odes9, J. Pfeffer10, Z. Levy11, E. Israeli12, I. Dotan13, D. Turner*2

1Shaare Zedek Medical Center, The Juliet Keiden Institute of Pediatric Gastroenterology and Nutrition, Jerusalem, Israel, 2Shaare Zedek Medical Center, Juliet Keidan Institute of Pediatric Gastroenterology and Nutrition, Jerusalem, Israel, 3Rambam Health Care Campus & Bruce Rappaport School of Medicine, Technion Institute of Technology, Department of Gastroenterology, Haifa, Israel, 4Clalit Health Services, Clalit Research Institute, Chief Physician's Office, Tel-Aviv, Israel, 5Meuhedet Sick Fund, Medical division, Tel-Aviv, Israel, 6Leumit Health Fund, Community Medicine, Tel-Aviv, Israel, 7Maccabi Health Services, Medical Informatics, Tel-Aviv, Israel, 8Sheba Medical Center, Department of Gastroenterology, Tel Hashomer, Israel, 9Soroka Medical Center and Ben-Gurion University of the Negev, Department of Gastroenterology and Hepatology, Beer Sheva, Israel, 10Tel Aviv Medical Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel, Tel Aviv, Israel, 11Rabin Medical Center, Gastroenterology, Petach Tikva, Israel, 12Hadassah Medical Center, Gastroenterology, Jerusalem, Israel, 13Sackler Faculty of Medicine, Tel Aviv Israel, IBD Center, Department of Gastroenterology and Liver Diseases, Tel Aviv Sourasky Medical Center , Tel Aviv, Israel

DOP016.

Smoking cessation alters intestinal microbiota – further insights from quantitative investigations on human faecal samples using FISH and qPCR

Authors:

L. Biedermann1, K. Brülisauer2, J. Zeitz1, P. Frei1,3, M. Scharl1, S.R. Vavricka1,4, M. Fried1, M.J. Loessner2, G. Rogler1, M. Schuppler2, 1University Hospital Zurich, Gastroenterology & Hepatology, Zurich, Switzerland, 2ETH Zurich, Institute of Food, Nutrition and Health, Zurich, Switzerland, 3Seespital Horgen, Gastroenterology & Hepatology, Horgen, Switzerland, 4Hospital Triemli, Gastroenterology & Hepatology, Zurich, Switzerland

DOP016

Are extraintestinal manifestations associated with disease outcomes in Crohn's Disease? Results from a population based inception cohort between 1977-2012

Authors:

B. Lovasz*1, P.A. Golovics1, Z. Vegh1, I. Szita2, M. Balogh3, G. Rogler4, S. Vavricka4, L. Lakatos2, P. Lakatos1

1Semmelweis University, 1st Department of Medicine, Budapest, Hungary, 2Csolnoky F. Province Hospital, Department of Medicine, Veszprem, Hungary, 3Grof Eszterhazy Hospital, Department of Medicine, Papa, Hungary, 4University Hospital Zurich, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Zurich, Switzerland

DOP017.

Dysbiosis in ulcerative colitis: adding the spatial component

Authors:

A. Lavelle1,2, G. Lennon1,2, A. Balfe1,2, N. Docherty2, J. Hyland1, D. O'Donoghue1, G. Docherty1, O. O'Sullivan3, P. Cotter3, K. Sheahan1, H. Mulcahy1, F. Shanahan3, J.C. Coffey4, D. Winter1,2, P.R. O'Connell1,2, 1St. Vincent's University Hospital, Centre for Colorectal Disease, Dublin, Ireland, 2University College Dublin (UCD), School of Medicine and Medical Science, Dublin, Ireland, 3University College Cork, Alimentary Pharmabiotic Centre, Cork, Ireland, 4Graduate Entry Medical School, University Hospital Limerick, University of Limerick Ireland, Limerick, Ireland

DOP017

Disease behaviour in Crohn's disease patients diagnosed in the biological era - A Dutch population-based IBD-SL cohort study

Authors:

S. Jeuring*1, 2, T. Van den Heuvel1, 2, M. Zeegers3, 4, W. Hameeteman1, M. Romberg-Camps5, L. Oostenbrug6, A. Masclee1, 2, D. Jonkers1, 2, M. Pierik1, 2

1Maastricht University Medical Center+, Internal Medicine - Division Gastroenterology-Hepatology, Maastricht, Netherlands, 2Maastricht University Medical Center+, NUTRIM, School for Nutrition, Toxicology and Metabolism, Maastricht, Netherlands, 3University of Birmingham, Public Health, Epidemiology and Biostatistics, Birmingham, United Kingdom, 4Maastricht University Medical Center+, Complex Genetics, Cluster of Genetics and Cell Biology, Maastricht, Netherlands, 5Orbis Medical Center, Gastroenterology and Hepatology, Sittard, Netherlands, 6Atrium Medical Center, Internal Medicine and Gastroenterology, Heerlen, Netherlands

DOP018.

Low microbial diversity in Crohn's disease is due to striking depletion of unknown species

Authors:

N. Borruel1, H.B. Nielsen2, F. Casellas1, C. Manichanh3, E. Varela3, M. Antolín3, A. Torrejón1, V. Robles1, P. Nos4, X. Calvet5, F. Guarner1, MetaHIT Consortium6, 1Hospital Vall d'Hebron, Crohn's and Colitis Attention Unit. Digestive System Research Unit, Barcelona, Spain, 2Technical University of Denmark, Center for Biological Sequence Analysis, Department of Systems Biology, Lyngby, Denmark, 3Hospital Vall d'Hebron, Digestive System Research Unit, Barcelona, Spain, 4Hospital Universitari i Politècnic La Fe, Servicio de Medicina Digestiva, Valencia, Spain, 5Corporació Sanitària Parc Taulí, Servei d'Aparell Digestiu, Sabadell, Spain, 6MetaHIT Network, Partner Centres, Paris, France

DOP018

A 17-year prospective cohort study of paediatric inflammatory bowel disease patients diagnosed less than 10 years of age (Paris A1a)

Authors:

P. Henderson*1, P. Rogers2, D.C. Wilson1

1University of Edinburgh, Child Life and Health, Edinburgh, United Kingdom, 2Royal Hospital for Sick Children, Paediatric Gastroenterology, Edinburgh, United Kingdom

DOP019.

The relevance of population based IBD biobanks: a meta-analysis and introduction of the IBD-SL biobank cohort

Authors:

T. van den Heuvel1,2, D. Jonkers1,2, S. Jeuring1,2, W. Hameeteman1, L. Oostenbrug3, M. Romberg-Camps4, A. Masclee1,2, M. Zeegers5,6, M. Pierik1,2, 1Maastricht University Medical Center+, Internal Medicine – Division Gastroenterology-Hepatology, Maastricht, Netherlands, 2Maastricht University Medical Center+, NUTRIM, School for Nutrition, Toxicology and Metabolism, Maastricht, Netherlands, 3Atrium Medical Center, Internal Medicine and Gastroenterology, Heerlen, Netherlands, 4Orbis Medical Centre, Gastroenterology and Hepatology, Sittard-Geleen, Netherlands, 5Maastricht University Medical Center+, Complex Genetics, Cluster of Genetics and Cell Biology, Maastricht, Netherlands, 6University of Birmingham, Public Health, Epidemiology and Biostatistics, Birmingham, United Kingdom

DOP019

Opportunistic infections in inflammatory bowel disease (IBD): relevance of immunosuppressive therapy and mortality

Authors:

Y. Zabana*1, 2, L. Rodríguez3, T. Lobatón4, M. Martínez5, A. Montserrat6, R. Mena7, M. Dotti1, O. Benitez1, J. Guardiola3, E. Domènech2, 4, E. Garcia-Planella5, X. Calvet2, 6, M. Piqueras7, M. Aceituno1, 2, F. Fernández-Bañares1, 2, M. Esteve1, 2

1Hospital Universitari Mútua Terrassa, Gastroenterology Department, Terrassa, Spain, 2Centro de Investigación Biomédica en Red sobre enfermedades hepáticas y digestivas, CIBERehd, Madrid, Spain, 3Hospital Universitari Bellvitge, Gastroenterology Department, Barcelona, Spain, 4Hospital Universitari Germans Trias i Pujol, Gastroenterology Department, Badalona, Spain, 5Hospital de Santa Creu i Sant Pau, Gastroenterology Department, Barcelona, Spain, 6Corporació Sanitària Parc Taulí, Gastroenterology Department, Sabadell, Spain, 7Consorci Sanitari de Terrassa, Gastroenterology Department, Terrassa, Spain

DOP020.

The prevalence of paediatric inflammatory bowel disease: a systematic review

Authors:

F.L. Cameron, P. Henderson, D.C. Wilson, University of Edinburgh, Child Life and Health, Edinburgh, United Kingdom

DOP020

The prevalence of autoimmune diseases in a nationwide paediatric inflammatory bowel disease cohort

Authors:

V. Merrick*1, P. Henderson1, H. Drummond2, J. Van Limbergen3, R. Russell4, J. Satsangi2, D. Wilson1

1University of Edinburgh, Child Life and Health, Edinburgh, United Kingdom, 2University of Edinburgh, Gastrointestinal Unit, Centre for Genomic and Experimental Medicine, Edinburgh, United Kingdom, 3Dalhousie University, Department of Pediatrics, Halifax, Canada, 4Royal Hospital for Sick Children, Paediatric Gastroenterology, Glasgow, United Kingdom

DOP021.

Familial risk of inflammatory bowel disease: a population-based cohort study 1977–2011

Authors:

F. Trier Moller1,2, V. Andersen3, T. Jess2, 1Southern University of Denmark, Institute for Regional Health Research, Odense, Denmark, 2Statens Serum Institut, Department of Epidemiology Research, Copenhagen, Denmark, 3Southern University of Denmark, Institute for Regional Health Research – SHS, Odense, Denmark

DOP021

Risk of liver fibrosis in Crohn's Disease patients treated with methotrexate: A case-control study

Authors:

J. Llaó*1, A. Bargallo2, C. Romero3, M. Mañosa4, J. Haya3, L. Yip1, E. Cabre2, E. García-Planella3, E. Domenech2

1Hospital de la Santa Creu i de Sant Pau, Inflamatory bowel disease, Barcelona, Spain, 2Hospital Germans Trias i Pujol, Gastroenterology, Badalona, Spain, 3Hospital de la Santa Creu i Sant Pau, Gastroenterology, Barcelona, Spain, 4Hospital germans Trias i Pujol, Gastroenterology, Barcelona, Spain

DOP022.

Sexual behaviours in patients attending an IBD clinic – should we ask about it?

Authors:

A. Morieux1, C. Mowat2, N. Reynolds2, J. Todd2, A. Meritsi2, S. Allstaff3, M. Groome2, 1University of Dundee Medical School, Medical School, Dundee, United Kingdom, 2Ninewells Hospital & Medical School, Gastroenterology, Dundee, United Kingdom, 3Ninewells Hospital & Medical School, Sexual & Reproductive Health, Dundee, United Kingdom

DOP022

Incidence of and risk factors for thromboembolism in Inflammatory Bowel Disease: Results from a population-based inception cohort

Authors:

Z. Vegh*1, P.A. Golovics1, Z. Kurti1, B. Lovasz1, I. Szita2, M. Balogh3, T. Pandur2, K. Gecse1, L. Lakatos2, P. Lakatos1

1Semmelweis University, 1st Department of Medicine, Budapest, Hungary, 2Csolnoky F. Province Hospital, Department of Medicine, Veszprem, Hungary, 3Grof Eszterhazy Hospital, Department of Medicine, Papa, Hungary

DOP023.

Preconception care in IBD women leads to less disease relapses during pregnancy

Authors:

A. de Lima1, Z. Zelinkova1,2, C. van der Ent1, C.J. van der Woude1, 1Erasmus Medical Center, Gastroenterology and Hepatology, Rotterdam, Netherlands, 2University Hospital, 5th Department of Internal Medicine, Gastroenterology Unit, Bratislava, Slovakia

DOP023

Evaluation of global coagulation profiles in patients with acute severe colitis: Implications for thromboprophylaxis

Authors:

B. Griffiths*1, N. Curry2, M. Desborough2, S. Henton2, R.V. Bryant1, S.P. Travis1, V. Jairath1

1Oxford University Hospitals NHS Trust, Translational Gastroenterology Unit, Oxford, United Kingdom, 2Oxford University Hospitals NHS Trust, Oxford Haemophillia & Thrombosis Centre, Oxford, United Kingdom